icaritin (SNG-162)

News alerts, weekly reports and conference planners

Company:

Shenogen Pharma

Drug class:

ER-α 36 modulator

‹

›

PD-L1 expression	Hepatocellular Cancer	PD-L1 expression	Hepatocellular Cancer	SNG-162 Sensitive: C2 – Inclusion Criteria SNG-162 Sensitive : C2	SNG-162 Sensitive: C2 – Inclusion Criteria SNG-162 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	SNG-162 Sensitive: D – Preclinical SNG-162 Sensitive : D	SNG-162 Sensitive: D – Preclinical SNG-162 Sensitive : D

Associations
(2)